🚨 FDA Approves Generic Rivaroxaban (Xarelto) 2.5 mg. The FDA has approved the first generic version of rivaroxaban (Xarelto) 2.5 mg, a dosage used to reduce the risk of major cardiovascular events in people with coronary artery disease (CAD) and major thrombotic vascular events in people with peripheral artery disease (PAD). What this means: This approval provides more affordable options for patients with CAD and PAD who rely on rivaroxaban. ⚠️ Important note: This approval does not apply to pe